Dr. Deirdre Hooper, M.D.
Dermatology (Dermatology Physician)
- Medicare participating
At a glance
- Medical school
- Louisiana State University School of Medicine in New Orleans (1999)
- Years since graduation
- 27
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 223
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1999Medical school: Louisiana State University School of Medicine in New Orleans
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
LA license 024358
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Audubon Dermatology, LLC (3 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 223
- Services billed
- 1,222
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 499 | 69 |
| Established patient office or other outpatient visit, 20-29 minutes | 224 | 159 |
| Destruction of precancer skin growth, 1 growth | 130 | 91 |
| Biopsy of related skin growth, first growth | 101 | 82 |
| Biopsy of related skin growth, each additional growth | 32 | 22 |
| New patient office or other outpatient visit, 30-44 minutes | 29 | 29 |
| Destruction of skin growth, 1-14 growths | 28 | 26 |
| Established patient office or other outpatient visit, 30-39 minutes | 27 | 25 |
| Established patient office or other outpatient visit, 10-19 minutes | 24 | 23 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 18 companies reported 58 payments worth $9,512 in total to this clinician.
| Galderma Laboratories, L.P. | $6,748 |
|---|---|
| AbbVie Inc. | $1,903 |
| Revance Therapeutics, Inc. | $338 |
| Janssen Biotech, Inc. | $103 |
| Incyte Corporation | $50.27 |
| Leo Pharma Inc. | $47.56 |
| Arcutis Biotherapeutics, Inc. | $41.09 |
| Sun Pharmaceutical Industries Inc. | $37.96 |
| Consulting Fee | $7,925 |
|---|---|
| Food and Beverage | $1,321 |
| Travel and Lodging | $267 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Galderma Laboratories, L.P. Jul 26, 2025 | Consulting Fee | $6,400 |
| AbbVie Inc. Dec 4, 2025 | Consulting Fee | $1,000 |
| AbbVie Inc. Oct 1, 2025 | Consulting Fee | $525 |
| Galderma Laboratories, L.P. Jul 26, 2025 | Travel and Lodging travel to DALLAS, TX | $267 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 3 companies. The companies reported $352,321 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVÉDERM® Products, KYBELLA, CoolSculpting Elite and SkinMedica Products
AbbVie Inc. · Completed · NCT06783621 - A Study to Assess BOTOX Injections in Adult Participants for the Change of Masseter Muscle Prominence
AbbVie Inc. · Completed · NCT06387394 - M21-416 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study
AbbVie Inc. - A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria
Incyte Corporation - M24-704 - A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US …
AbbVie Inc. - A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony)
AbbVie Inc. - JUVÉDERM® VOLITE™ XC Injectable Gel for Improvement in Neck Appearance
AbbVie Inc. · Completed · NCT05316233 - A phase 3 randomized withdrawal and doseup titration multicenter extension study investigating the safety efficacy and tolerability of ritlecitinib in adult and adolescent participants with nonsegmental vitiligo
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.